Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Colombia
100%
Cost-effectiveness
100%
HER2-positive
100%
Liquid Biopsy
100%
Advanced Breast Cancer
100%
Treatment Change
100%
Quality-adjusted Life Years
42%
Circulating Tumor DNA (ctDNA)
42%
Breast Cancer
28%
Conventional Treatment
28%
HER2-targeted Therapy
28%
HER2-positive Advanced Breast Cancer
28%
Price Information
14%
High Specificity
14%
Clinical Manifestations
14%
Pharmacological Treatment
14%
Literature Search
14%
Economic Evaluation
14%
High Sensitivity
14%
Treatment Costs
14%
Poor Prognosis
14%
Minimally Invasive
14%
Deterministic Analysis
14%
Current Costs
14%
Window of Opportunity
14%
T-DM1
14%
Trastuzumab
14%
Docetaxel
14%
Drug Costs
14%
Incremental Cost
14%
Treatment Resistance
14%
Molecular Treatment
14%
Pertuzumab
14%
Modeling Analysis
14%
Decision Tree Model
14%
Colombian
14%
Easily Accessible
14%
Treatment Lines
14%
Healthcare Costs
14%
HER2-positive Subtype
14%
Local Studies
14%
Financial Capacity
14%
Molecular Resistance
14%
Medicine and Dentistry
Health Care Cost
100%
Breast Cancer
100%
Liquid Biopsy
100%
Quality Adjusted Life Year
37%
Chloroplast DNA
37%
Sensitivity and Specificity
25%
Drug Therapy
12%
Docetaxel
12%
Pertuzumab
12%
Trastuzumab
12%
Nursing and Health Professions
Breast Cancer
100%
Liquid Biopsy
100%
Quality Adjusted Life Year
42%
Chloroplast DNA
42%
Sensitivity and Specificity
28%
Drug Therapy
14%
Information Systems
14%
Health Care Cost
14%
Decision Tree
14%
Economic Evaluation
14%
Pertuzumab
14%
Docetaxel
14%
Trastuzumab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Chloroplast DNA
60%
Trastuzumab
20%
Pertuzumab
20%
Docetaxel
20%